In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

Regulus Therapeutics Inc.‘s up to $1.7 billion sale to Novartis AG was flawed, primarily benefiting board members and executives who have large amounts of illiquid shares instead of public ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

Novartis AG blocked MSN Laboratories Pvt. Ltd.’s attempt to launch a copy of its blockbuster Entresto before July 16, as a ...

Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients 1 Rising breast cancer diagnosis rates and more aggressive disease in ...